Authors

Latest:

Women in Oncology: The Value of Female Leadership

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss how they turned career obstacles into opportunities and what they have learned from being women in the leukemia field.

Michelle Miran Kim, MD

Latest:

Dr. Kim on Optimizing Individualized Treatment in Cancer Care

Michelle Miran Kim, MD, discusses optimizing individualized treatment in cancer care.

Jamie Carroll, APRN, CNP, MSN

Latest:

Novel Clinical Trials With ADCs in Gastric Cancer

Before closing out their discussion on HER2+ gastric cancer, experts review clinical trials investigating other novel ADC agents in this setting.

Elyse Lower, MD

Latest:

Dr. Lower on the Importance of Tucatinib Plus Capecitabine/Trastuzumab in HER2+ Breast Cancer

Elyse Lower, MD, discusses the importance of tucatinib in the treatment of patients with HER2-positive breast cancer.

Melissa Zinszer, PharmD, CDCES

Mahasweta Gooptu, MD

Latest:

Monitoring and Follow-Up of Patients with Chronic GVHD

The panel closes by reviewing the patient case once more and shares clinical pearls on the treatment of patients with GVHD.

Charles B. Nguyen, MD

Charles B. Nguyen, MD, is an assistant clinical professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Irvine, California.

Latest:

Dr Nguyen on the Evolving Landscape of Adjuvant Therapy in Localized ccRCC

Charles B. Nguyen, MD, discusses the evolving landscape of adjuvant therapy in localized clear cell renal cell carcinoma.

Roberto Iacovelli, MD, PhD

Latest:

Dr. Iacovelli on Eligibility Criteria of the ARIES Trial in Urothelial Cancer

Roberto Iacovelli, MD, PhD, discusses the patient eligibility criteria of the phase 2 ARIES trial in urothelial cancer.

Lucia Masarova, MD

Latest:

Dr Masarova on the Investigation of Ropeginterferon Alfa in Essential Thrombocythemia

Lucia Masarova, MD, discusses the investigation of ropeginterferon alfa in adult patients with essential thrombocythemia, highlighting the unmet needs that investigators aim to address with this investigation.

Sunil Iyer, MD

Latest:

Dr Iyer on the Mechanism of Action of Imetelstat in Lower-Risk MDS

Sunil Iyer, MD, discusses the mechanism of action of imetelstat in patients with lower-risk myelodysplastic syndrome with anemia.

Arvin K. George, MD

Arvin K. George, MD is director of Prostate Cancer Programs and an associate professor of clinical urology at Johns Hopkins School of Medicine.

Latest:

Dr George on Early Insights and Future Directions for Water Vapor Thermal Therapy in Prostate Cancer

Arvin K. George, MD, discusses the mechanism of water vapor thermal therapy and the implications of VAPOR 2 findings in prostate cancer management.

Antonio Cigliola, MD

Latest:

Dr Cigliola on Potential Implications of the SURE-01 and SURE-02 Trials in MIBC

Antonio Cigliola, MD, discusses potential clinical implications of data from the phase 2 SURE-01 and SURE-02 trials in MIBC.

Christina S. Baik, MD, MPH

Latest:

Dr Baik on the Clinical Utility of Zongertinib in Previously Treated HER2-Mutant NSCLC

Christina S. Baik, MD, MPH, discusses the clinical utility of zongertinib in previously treated non–small cell lung cancer harboring HER2 TKD mutations.

Benjamin Creelan, MD

Latest:

Dr Creelan on the Promise of Cemiplimab in Squamous NSCLC

Ben Creelan, MD, discusses survival outcomes with cemiplimab in patients with squamous non–small cell lung cancer.

Joseph Vento, MD

Joseph Vento, MD, is an assistant professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center in Dallas.

Latest:

Dr Vento on the Clinical Significance of Somatic NGS in Guiding Treatment Decisions for Non–Clear Cell RCC

Joseph Vento, MD, discusses the importance of using somatic NGS to guide treatment decision-making for patients with non–clear cell RCC.

Kari Hacker, MD, PhD

Latest:

Dr Hacker on the Proportion of HER2-Expressing Tumors in Endometrial Cancer

Kari Hacker, MD, PhD, discusses the proportion of HER2-expressing endometrial cancers eligible for HER2-targeted antibody-drug conjugate treatment.

Juan Vasquez, MD

Juan Vasquez, MD, is an assistant professor of Pediatrics (Hematology/Oncology) and the associate program director of the Pediatrics Hematology/Oncology Fellowship at Yale School of Medicine.

Latest:

Dr Vasquez on the Rationale for Investigating NAMPT Inhibition in Rhabdomyosarcoma

Juan Vasquez, MD, discussed unmet needs for patients with pediatric rhabdomyosarcoma that investigations of NAMPT inhibition may address.

Christopher S. Lathan, MD, MS, MPH

Latest:

Dr Lathan on Community-based Cancer Evaluation Services in Underserved Patient Groups

Christopher Lathan, MD, MS, MPH, discusses socioeconomical and clinical findings from a clinical outreach program incorporating cancer diagnostic services and patient navigation for patients from traditionally underserved populations.

Whitfield B. Growdon, MD

Latest:

Dr Growdon on the Withdrawal of Later-Line Indication For Olaparib in BRCA-Mutated Ovarian Cancer

Whitfield B. Growdon, MD, expands on the FDA’s decision to withdraw the later-line indication of olaparib for patients with BRCA-mutated ovarian cancer.

Jobelle Baldonado, MD

Latest:

Dr Baldonado on the Evolution of Targeted Therapy in NSCLC

Jobelle Baldonado, MD, discusses the evolution of personalized approaches to treatment in non–small cell lung cancer.